West Pharmaceutical Services (WST) Accounts Payables (2009 - 2026)

West Pharmaceutical Services (WST) has reported Accounts Payables for 18 consecutive years, with $252.7 million the latest figure, recorded in Q2 2026.

• Quarterly Accounts Payables rose 5.73% year-over-year to $252.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $252.7 million (up 5.73% YoY) and the FY2025 annual result came in at $253.7 million, up 6.02% from the prior year.
• Accounts Payables steadied at $252.7 million in Q2 2026 per WST's latest filing, from $252.3 million in the prior quarter.
• Over the last five years, Accounts Payables for WST reached as high as $255.8 million in Q3 2025 and fell as low as $188.9 million in Q3 2022.
• A 5-year average of $232.4 million and a median of $236.4 million in 2023 frame the typical range for Accounts Payables.
• The largest YoY upside for Accounts Payables was 21.49% in 2022 against a maximum downside of 9.05% in 2022.
• Year by year, Accounts Payables stood at $215.4 million in 2022, then gained by 12.53% to $242.4 million in 2023, then slipped by 1.28% to $239.3 million in 2024, then increased by 6.02% to $253.7 million in 2025, then decreased by 0.39% to $252.7 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $252.7 million, $252.3 million, and $253.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.